A 29-years-old man was diagnosed with Philadelphia negative pre B ALL with no CNS involvement in August 2017. He was treated with a pediatric-inspired protocol and achieved remission; however, he had isolated CNS relapse while on maintenance therapy. He received salvage chemotherapy with fludarabine and Ara-C, and upon remission, he was consolidated with matched sibling allo-HCT using MAC with Cy/TBI; GVHD prophylaxis consisted of methotrexate and CSA. His course was complicated by grade II, steroid-responsive acute gut and skin GVHD as well as CMV colitis. Day 170 post HCT (June 5, 2020) while he was on tapering tacrolimus, he developed fever, cough, headache, runny nose followed by loss of taste and smell. He tested positive by PCR for SARS-Cov2 infection. Chest x-ray showed small faint ground-glass opacity in the left lower lung zone. Tacrolimus was stopped, and he was treated with ceftriaxone, hydroxychloroquine(HCQ), and azithromycin. He improved after 7days and was discharged. Repeat nasal SARS-Cov2 PCRs on July 8, 2020, were negative, and his SARS-Cov2 total antibody test was reactive on July 25, 2020. Unfortunately, on August 7, 2020, he was diagnosed with relapsed ALL, and currently, he is receiving blinatumomab salvage.